Forteo

DRUG6 trials

Sponsors

University of Michigan, Pfizer, Eli Lilly and Company, University Health Network, Toronto, Zosano Pharma Corporation

Conditions

Bone LossHealthy VolunteersOsteoporosisPeriodontitisPostmenopausal Osteoporosis

Phase 1

Impact of Parathyroid Hormone (PTH) on Osseous Cavity

CompletedNCT00277706

University of MichiganBone Loss, Periodontitis

Start: 2004-08-31End: 2009-07-31Target: 40Updated: 2009-10-07

A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen

CompletedNCT02478879

Zosano Pharma CorporationPostmenopausal Osteoporosis

Start: 2015-06-30End: 2015-12-31Target: 24Updated: 2016-08-23

Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule

CompletedNCT05164614

RANI TherapeuticsHealthy Volunteers

Start: 2022-02-21End: 2022-10-17Updated: 2022-10-31

Unknown Phase

A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Forteo

CompletedNCT00365924

PfizerOsteoporosis

Start: 2006-12-31End: 2008-04-30Updated: 2009-03-23

Study of FORTEO Use in Subjects in the Community Setting

CompletedNCT01078805

Eli Lilly and CompanyOsteoporosis

Start: 2003-08-31End: 2011-02-28Updated: 2012-06-26

Teriparatide (PTH) and Bone Strength in Postmenopausal Women

University Health Network, TorontoOsteoporosis

Start: 2008-06-30End: 2025-01-31Target: 60Updated: 2024-05-17

Related Papers

Teriparatide and osseous regeneration in the oral cavity.

2010-10-16184 citations